Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines

Leukemia Research

Volumn 27, Issue 7, 2003, Pages 617-626

  Pearlman, Michael ^a   Jendiroba, David ^a   Pagliaro, Lance ^a   Keyhani, Afsaneh ^a   Liu, Baoshun ^a   Freireich, Emil J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute leukemia therapy; Cytotoxicity; Dexrazoxane; Doxorubicin; In vitro

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; RAZOXANE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL LINE; COLONY FORMATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STEM CELL;

EID: 0037411223     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00273-4     Document Type: Article

References (28)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer Statistics, 2002. CA Cancer J. Clin. 52(1):2002;23-47.
2. Neglia J. Epidemiology of childhood acute leukemias. Pediatr. Clin. North Am. 35:1988;675-692.
3. Freireich E.J. Acute leukemia: a prototype of dissemintaed cancer. Cancer. 53:1984;2026-2033.
4. Pharmacia. Pharmacia investigators' brochure for Zinecard (dexrazoxane). 1996.
5. Koeller J.M., Earhart R.H., Davis H.L. Phase I trial of ICRF-187 by 48-h continuous infusion. Cancer Treat. Rep. 65(5/6):1981;459-463.
6. Hasinoff B.B., Hellmann K., Herman E.H., Ferrans V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5(1):1998;1-28.
7. Nara N. The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. Blood. 65:1985;1484-1493.
8. Buick R. Colony assay proliferative blast cells circulating in myeloblastic leukemia. Lancet. 1:1977;862-863.
9. Chou T. Quantitiative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
10. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 25:1998;10-21.
11. Eliot H. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry. 23:1984;928.
12. Batist G. Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parental nutrition. Cancer Res. 45:1985;5900-5903.
13. Muindi J. hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett. 172:1984;226-230.
14. Muindi J., Sinha B.K., Gianni L., Myers C. Thiol-dependent DNA damage produced by anthracycline-iron complexes: the structure-activity relationships and molecular mechanisms. Mol. Pharmacol. 27:1985;356-365.
15. Myers C. Oxidative damage of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry. 21:1982;1707-1712.
16. Myers C. Anthracyclines. Cancer Chemother. 8:1986;52-64.
17. Myers C.E., Muindi J.R., Zweier J., Sinha B.K. 5-Iminodaunomycin. An anthracycline with unique properties. J. Biol. Chem. 262:1987;11571-11577.
18. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochim. Biophys. Acta. 884:1986;326-336.
19. Rajagopalan S., Politi P.M., Sinha B.K., Myers C.E. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 48(17):1988;4766-4769.
20. Hasinoff B.B., Yalowich J.C., Ling Y., Buss J.L. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs. 7(5):1996;558-567.
21. Holm B., Jensen P.B., Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol. 38(3):1996;203-209.
22. Hellmann K. Overview and historical development of dexrazoxane. Semin. Oncol. 25(4 Suppl 10):1998;48-54.
23. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S., Bianchine J.R., Gams R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 15(4):1997;1333-1340.
24. Budman D.R., Calabro A., Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? Leukemia. 15:2001;1517-1520.
25. Wadler S., Green M.D., Muggia F.M. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (Icrf 187) against the murine sarcoma S180 cell line. Cancer Res. 46(3):1986;1176-1181.
26. Monti E., Sinha B.K. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (Icrf-187) in human leukemic Hl-60 cells. Cancer Commun. 2(4):1990;145-149.
27. Scambia G., Della Bitta R., Benedetti Panici P., De Vincenzo R., Contu G., Ercoli A., Bonanno G., Pierelli L., Mancuso S. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol. Oncol. 57(1):1995;16-22.
28. Wang G., Finch M.D., Trevan D., Hellmann K. Reduction of daunomycin toxicity by razoxane. Br. J. Cancer. 43(6):1981;871-877.